Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14549598 | 0.98 | NFE2L2 (0.96) | NFE2L2HPGDHRH3GRM2MCHR1 | |
| SCHEMBL22260017 | 0.91 | NFE2L2 (0.84) | NFE2L2HPGDHRH3LTA4HPTGS1 | |
| SCHEMBL2562093 | 0.91 | NFE2L2 (0.83) | NFE2L2HPGDMCHR1LTA4HPTGS1 | |
| SCHEMBL507318 | 0.83 | NFE2L2 (0.71) | NFE2L2HPGDHRH3GRM2MCHR1 | |
| SCHEMBL15651091 | 0.83 | NFE2L2 (0.71) | NFE2L2TDP1 | |
| SCHEMBL23163613 | 0.82 | NFE2L2 (0.70) | NFE2L2HPGDHRH3GRM2LTA4H | |
| SCHEMBL35212115 | 0.82 | NFE2L2 (0.70) | NFE2L2HPGDHRH3GRM2 | |
| SCHEMBL30674515 | 0.82 | NFE2L2 (0.70) | NFE2L2HPGDHRH3GRM2LTA4H | |
| SCHEMBL30674771 | 0.82 | NFE2L2 (0.70) | NFE2L2HPGDHRH3GRM2 | |
| SCHEMBL30674531 | 0.82 | NFE2L2 (0.70) | NFE2L2HPGDHRH3GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220003753-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ADS PHENOTYPE 1 | STALICLA SA (CH) | 2022-01-06 | — | — | US | claimed |
| EP-3877540-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ASD PHENOTYPE 1 | Stalicla S.A. (CH) | 2021-09-15 | — | — | EP | claimed |
| US-11040117-B2 | Treatment of a subtype of ASD | Stalicla S.A. (CH) | 2021-06-22 | — | — | US | claimed |
| US-20210169993-A1 | TREATMENT OF A SUBTYPE OF ASD | STALICLA SA (CH) | 2021-06-10 | — | — | US | claimed |
| EP-3706807-A1 | TREATMENT OF A SUBTYPE OF ASD | Stalicla S.A. (CH) | 2020-09-16 | — | — | EP | claimed |
| US-20190134152-A1 | TREATMENT OF A SUBTYPE OF ASD | Stalicla S.A. (CH) | 2019-05-09 | — | — | US | claimed |
| US-12474327-B2 | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1 | STALICLA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20220003753-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ADS PHENOTYPE 1 | STALICLA SA (CH) | 2022-01-06 | — | — | US | disclosed |
| EP-3877540-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ASD PHENOTYPE 1 | Stalicla S.A. (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-11040117-B2 | Treatment of a subtype of ASD | Stalicla S.A. (CH) | 2021-06-22 | — | — | US | disclosed |
| US-20210169993-A1 | TREATMENT OF A SUBTYPE OF ASD | STALICLA SA (CH) | 2021-06-10 | — | — | US | disclosed |
| EP-3706807-A1 | TREATMENT OF A SUBTYPE OF ASD | Stalicla S.A. (CH) | 2020-09-16 | — | — | EP | disclosed |
| US-20190134152-A1 | TREATMENT OF A SUBTYPE OF ASD | Stalicla S.A. (CH) | 2019-05-09 | — | — | US | disclosed |